Expert Interview
Discussing the standard of care and/or the potential of semaglutide to treat chronic kidney disease and Novo Nordisk's decision to stop their semaglutide kidney outcomes trial, FLOW
Ticker(s): NVOInstitution: University of Iowa
- Clinical Professor of Internal Medicine - Nephrology, and Medical Director for dialysis at University of Iowa
- Clinical work involves all aspects of care for patients with kidney diseases (including transplant, kidney stones, general nephrology and dialysis) both in an inpatient and outpatient setting
- Teaching role involves formal/class and bedside/clinical education for students, residents of different specialties, nephrology fellows as well as peers.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
